https://aspenpharma.com

Aspen Pharmacare | Pharmaceutical CompanyAspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed marketsAspen Pharmacare | Pharmaceutical Company Share Price: APNASPENAspen Pharmacare Hldgs142490 (0.00%) Search Close this search box. Our Response to Covid Country Sites About Aspen About Aspen Corporate Governance Regional Overviews Our Leadership Global Presence Business Segments Corporate Governance The Board is accountable to shareholders and other stakeholders and is ultimately responsible for the implementation of sound corporate governance practices throughout the Group. Aspen’s Board of Directors is committed to ensuring that the Group adheres to high standards of corporate governance in the conduct of its business. Regional Overview Africa Middle East Americas Asia Australasia Europe CIS Business Segments Prescription Over the Counter Injectables Manufacturing Manufacturing Aspen has 23 manufacturing facilities across 15 sites. Ourstrategic manufacturing sites are widely accredited, holding international approval from some of the most stringent global regulatory agencies. We manufacture a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and APIs. Interim Results Presentation Webcast Register for Webcast Read More » FY2026 Interim Results Presentation View or Download Read More » Investor Relations Investor Relations Investor Hub Financial Information Financial Results and Presentations Integrated Reporting Share Price Information Financial Calendar SENS Investor Relations Access our investor hub for information and tools including corporate reporting, share price, dividends, calendar, SENS and other relevant documents. Interim Results Presentation Webcast Register for Webcast Read More » FY2026 Interim Results Presentation View or Download Read More » We Care We Care Ethics & Compliance Management SED Initiatives Mandela Day Sustainability Responsible Corporate Citizenship Ethics & Compliance Management “A bright future beckons. The onus is on us, through hard work, honesty, and integrity, to reach for the stars. ” – Nelson Mandela SED Initiatives Aspen has demonstrated an unwavering commitment to our credo ‘Healthcare. We Care” through a wide range of initiatives and activities that span more than two decades. Mandela Day DURBAN – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded pharmaceutical company, has hosted more than 800 activities over 12 years in celebration of the annual Nelson Mandela International Day (“Mandela Day”). Our Sustainability Commitments We believe that doing business in a sustainable and responsible manner is integral to our purpose, our values and our philosophy “Healthcare. We Care”. Our sustainability commitments are integrated into the Group’s strategic objectives and underpin the way we do business. Interim Results Presentation Webcast Register for Webcast Read More » FY2026 Interim Results Presentation View or Download Read More » Careers Careers Careers at Aspen Aspen Jobs Bursary Applications High Performing, Inclusive Culture Our purpose is to deliver a differentiated portfolio of high quality and affordable medicines to improve the health and quality of life of patients across the markets we operate and how we show up every day to achieve this has shaped a culture of agility, high performance and inclusion. Working At Aspen We believe that doing business in a sustainable and responsible manner is integral to our purpose, our values and our philosophy “Healthcare. We Care”.  Our sustainability commitments are integrated into the Group’s strategic objectives and underpin the way we do business and how we show up every day, across the world. Bursary Applications Aligned with our philosophy of “Healthcare. We Care”, Aspen supports education as a way of empowering people. We offer certain bursary opportunities in South Africa for specific qualifications offered at specific institutions. Interim Results Presentation Webcast Register for Webcast Read More » FY2026 Interim Results Presentation View or Download Read More » Media Media Press Releases Our Stories Media Coverage Aspen Holding News Aspen delivers encouraging results, driven by strong Commercial Pharma, reshaped Manufacturing and value realisation from APAC divestment Proposed divestment of Aspen Asia Pacific (excluding China) for R26.5 billion Stephen Saad receives both AABLA Lifetime Achievement Award and African of the Year Award Aspen highlights the rising diabetes disease burden Aspen building momentum in Commercial Pharmaceuticals and Manufacturing strategy modified Aspen celebrates 15 years of commitment to Nelson Mandela Day Aspen delivers strong results and advances its strategic ambitions Aspen announces local availability of Lilly’s Mounjaro Aspen and SEMDSA highlight the alarming rise of non-communicable diseases on World Diabetes Day Aspen to participate in the Investec CEO conference in London Aspen partners with PinkDrive to mobilise cancer screening Aspen’s revenue increases 10% underpinned by a strong second half performance Interim Results Presentation Webcast Register for Webcast Read More » FY2026 Interim Results Presentation View or Download Read More » Contact Us About Aspen About Aspen Corporate Governance Regional Overviews Our Leadership Global Presence Business Segments Corporate Governance The Board is accountable to shareholders and other stakeholders and is ultimately responsible for the implementation of sound corporate governance practices throughout the Group. Aspen’s Board of Directors is committed to ensuring that the Group adheres to high standards of corporate governance in the conduct of its business. Regional Overview Africa Middle East Americas Asia Australasia Europe CIS Business Segments Prescription Over the Counter Injectables Manufacturing Manufacturing Aspen has 23 manufacturing facilities across 15 sites. Ourstrategic manufacturing sites are widely accredited, holding international approval from some of the most stringent global regulatory agencies. We manufacture a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and APIs. Interim Results Presentation Webcast Register for Webcast Read More » FY2026 Interim Results Presentation View or Download Read More » Investor Relations Investor Relations Investor Hub Financial Information Financial Results and Presentations Integrated Reporting Share Price Information Financial Calendar SENS Investor Relations Access our investor hub for information and tools including corporate reporting, share price, dividends, calendar, SENS and other relevant documents. Interim Results Presentation Webcast Register for Webcast Read More » FY2026 Interim Results Presentation View or Download Read More » We Care We Care Ethics & Compliance Management SED Initiatives Mandela Day Sustainability Responsible Corporate Citizenship Ethics & Compliance Management “A bright future beckons. The onus is on us, through hard work, honesty, and integrity, to reach for the stars. ” – Nelson Mandela SED Initiatives Aspen has demonstrated an unwavering commitment to our credo ‘Healthcare. We Care” through a wide range of initiatives and activities that span more than two decades. Mandela Day DURBAN – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded pharmaceutical company, has hosted more than 800 activities over 12 years in celebration of the annual Nelson Mandela International Day (“Mandela Day”). Our Sustainability Commitments We believe that doing business in a sustainable and responsible manner is integral to our purpose, our values and our philosophy “Healthcare. We Care”. Our sustainability commitments are integrated into the Group’s strategic objectives and underpin the way we do business. Interim Results Presentation Webcast Register for Webcast Read More » FY2026 Interim Results Presentation View or Download Read More » Careers Careers Careers at Aspen Aspen Jobs Bursary Applications High Performing, Inclusive Culture Our purpose is to deliver a differentiated portfolio of high quality and affordable medicines to improve the health and quality of life of patients across the markets we operate and how we show up every day to achieve this has shaped a culture of agility, high performance and inclusion. Working At Aspen We believe that doing business in a sustainable and responsible manner is integral to our purpose, our values and our philosophy “Healthcare. We Care”.  Our sustainability commitments are integrated into the Group’s strategic objectives and underpin the way we do business and how we show up every day, across the world. Bursary Applications Aligned with our philosophy of “Healthcare. We Care”, Aspen supports education as a way of empowering people. We offer certain bursary opportunities in South Africa for specific qualifications offered at specific institutions. Interim Results Presentation Webcast Register for Webcast Read More » FY2026 Interim Results Presentation View or Download Read More » Media Media Press Releases Our Stories Media Coverage Aspen Holding News Aspen delivers encouraging results, driven by strong Commercial Pharma, reshaped Manufacturing and value realisation from APAC divestment Proposed divestment of Aspen Asia Pacific (excluding China) for R26.5 billion Stephen Saad receives both AABLA Lifetime Achievement Award and African of the Year Award Aspen highlights the rising diabetes disease burden Aspen building momentum in Commercial Pharmaceuticals and Manufacturing strategy modified Aspen celebrates 15 years of commitment to Nelson Mandela Day Aspen delivers strong results and advances its strategic ambitions Aspen announces local availability of Lilly’s Mounjaro Aspen and SEMDSA highlight the alarming rise of non-communicable diseases on World Diabetes Day Aspen to participate in the Investec CEO conference in London Aspen partners with PinkDrive to mobilise cancer screening Aspen’s revenue increases 10% underpinned by a strong second half performance Interim Results Presentation Webcast Register for Webcast Read More » FY2026 Interim Results Presentation View or Download Read More » Contact Us Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026. Healthcare. We Care. Excellence Integrity Healthcare. We Care. Innovation Commitment Teamwork Interim Results Presentation Webcast Register for Webcast FY2026 Interim Results Presentation View or Download FY2026 Interim Results Booklet View or Download FY2026 Interim Results Short Form Announcement View or Download Healthcare. We Care. Our Heritage With a 170-year heritage, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. We have more than 9 500 employees at 66 established offices in over some 48 countries and territories and we improve the health of patients in more than 115 countries through our high quality, affordable medicines. Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments. Our key business segments are Manufacturing and Commercial Pharmaceuticals comprising Injectable products, Prescription and OTC medicines. Our manufacturing capabilities cover a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients.We operate 24 manufacturing facilities across 15 sites and we hold international manufacturing approvals from some of the most stringent global regulatory agencies including, among others, the United States Food and Drug Administration, the Australian Therapeutic Goods Administration and the European Directorate for the Quality of Medicines. Learn More Investor Hub Register For Alerts Board of Directors Group Executive Committee Financial Results Integrated Reporting Sustainability Documents Stephen Saad(61) Sean Capazorio(60) Reginald Haman(52) Kuseni Dlamini(58) Ben Kruger(66) Linda de Beer(56) Neo Dongwana(53) Themba Mkhwanazi(56) Chris Mortimer(65) Yvonne Muthien(69) David Redfern(59) Raeesa Khan(35) Stephen Saad (61) Group Chief Executive Qualifications:Appointed:Classification: CA(SA), PhD (Commerce) Honoris CausaJanuary 1999Executive director Further Information Stephen is a founding shareholder of the Aspen Group and his responsibilities include strategic positioning and global transactions, geographic expansion and product diversification of Aspen in developed and emerging markets as a leading multinational pharmaceutical company. Sean Capazorio (60) Group Chief Financial Officer Qualifications:Appointed:Classification: CA(SA), Advanced Taxation Certificate (UNISA)January 2022Executive director Further Information Sean is responsible for the strategic and financial well-being of the Group and all the Group’s finance functions across Aspen’s businesses. Reginald Haman (52) Qualifications:Appointed:Classification: MBA, PGDBA, ND, NHD, Graduate Diploma in Company DirectionMarch 2024Executive director Further Information Reginald leads Aspen’s Group enablement, shared services, and governance functions, including technology, people, and strategic business processes. He is an independent non-executive director of the Institute of Directors of Southern Africa and Sasria SOC Ltd. Reginald serves as a member of the Social & Ethics Committee. Kuseni Dlamini 58 Qualifications:Appointed: Classification: MPhil (Oxon), BSocSci (Hons) (Natal), Global Leadership for the 21st Century Programme (Harvard), Foundations for Leadership in the 21st Century (Yale)April 2012Independent non-executive, Board Chair Further Information Kuseni previously served as Chair of Massmart Holdings Limited and Times Media Group Limited and as well as Chief Executive Officer of Old Mutual South Africa and Emerging Markets. He brings a wealth of economic and business skills to the Board, having previously held positions as the head of Anglo American South Africa and Executive Chair of Richards Bay Coal Terminal Company.Kuseni is the former Chair of the South African National Parks and a former member of the Global Agenda Council on Economic Growth and Poverty Alleviation formed by the World Economic Forum. He is active in academic and professional bodies, which include the Council of the University of Pretoria, the South African Institute of International Affairs, and the advisory boards of the Gordon Institute of Business Science and Common Purpose.Kuseni is a member of the Remuneration & Nomination Committee and the Social & Ethics Committee. Ben Kruger (66) Qualifications: Appointed: Classification: BCom (Hons), CA(SA), Advanced Programme in Management (Harvard Business School)April 2019 Lead independent non-executive Further Information Ben joined Standard Corporate and Merchant Bank in 1985 and, after having fulfilled various leadership roles in corporate and investment banking, was appointed Chief Executive of Standard Bank Corporate and Investment Banking in 2001. In March 2013, Ben was appointed as Co-Chief Executive Officer of the Standard Bank Group Limited, and he retired from The Standard Bank Group on 31 December 2018. He currently serves as a Non-executive director on the boards of Standard Bank Group Limited and The Standard Bank of SA Limited and as a Non-executive director on the board of the JSE Limited. He is a member of the Institute of Directors of Southern Africa and served on the board of the International Institute of Finance.Ben is also a Member, and serves as Deputy Chair of the Council for the University of Pretoria. Linda de Beer (56) Qualifications:Appointed:Classification: CA(SA), MCom (Tax), CD(SA)July 2018Independent non-executive Further Information Linda has 15 years’ experience as an independent non-executive director on JSE listed boards. She currently serves on the boards of Momentum Group, Momentum Metropolitan Life Limited and Shoprite Holdings Limited. She was previously a member of numerous South African and international standard setting, oversight and corporate governance structures, including the King Committee, the JSE’s Financial Reporting Investigation Panel (Chair), the International Public Interest Oversight Board (Chair), and the International Valuations Standards Council (based in London). Linda serves as the Chair of the Remuneration & Nomination Committee and is a member of the Audit & Risk Committee. Neo Dongwana (53) Qualifications:Appointed:Classification: CA(SA), B.Com (Hons), MComMarch 2024Independent non-executive Further Information Neo currently serves as a non-executive director on the board of Nedbank Group Limited and Vukile Property Limited. She previously served as a Nonexecutive director and Chair of Barloworld Limited and the Takeover Regulation Panel and has held positions on various listed and unlisted boards across multiple industries and jurisdictions. Additionally, she was a member of the Education Committee of the Independent Regulatory Board for Auditors and the Financial Services Tribunal.She is also a member of the African Women Chartered Accountants. Neo serves as a member of the Audit & Risk Committee. Themba Mkhwanazi (56) Qualifications:Appointed:Classification: B.Eng (Hons)April 2019Independent non-executive Further Information Themba was appointed as the Chief Executive Officer of Kumba Iron Ore Limited, a member of the Anglo American Plc Group, in September 2016. Prior to this appointment, he held several senior executive positions at various companies, including Anglo American Coal South Africa, Rio Tinto Technology and Innovation, Rio Tinto Australia, and Huntsman Tioxide Southern Africa.Themba is a member of the Remuneration & Nomination Committee. Chris Mortimer (65) Qualifications:Appointed:Classification: BA, LLBJanuary 1999Non-executive Further Information Chris has been a full-time practicing attorney since 1988 and has substantial legal and commercial expertise. His intimate knowledge of the Group, its business operations and governance processes have been of immense benefit to Aspen over the years and he continues to serve the Board as a trusted adviser. As Chris’s firm is intermittently called upon to provide legal advice to the Group, he is classified as a non-independent non-executive director. Yvonne Muthien (69) Qualifications: Appointed:Classification: D.Phil (Oxon), MA, BA (Hons), Leadership Financial Organizations, Harvard Business SchoolDecember 2021Independent non-executive Further Information Yvonne currently serves as Chairperson of the Rhodes Food Group, and Chair of Mavovo Capital, as well as an independent non-executive director on the boards of the SA Reserve Bank and the SA SME Fund.She was also Chair of Bankserv and Chair of the Sasol Foundation, and non-executive director of Thebe Investment Corporation.Yvonne previously served as Chief Executive: Group Services at Sanlam and executive director of Sanlam Ltd as well as non-executive director of Santam, Sanlam Investments and Sanlam Investment Management. Preceding that she was Vice President of Coca-Cola Africa based in London and a Group Executive at the MTN Group Ltd.She also formerly served as a nonexecutive director of Aurecon, Sentech, MTN Nigeria, the SABC, and Transnet. Yvonne serves as the Chair of the Social & Ethics Committee and is a member of the Audit & Risk Committee. David Redfern (59)* Qualifications:Appointed:Classification: BSc (Hons), CAFebruary 2015Non-executive * British Further Information David was appointed President Corporate Development of GSK in May 2008 and is responsible for business development and strategic planning. He has, in this role, assisted GSK in numerous bolt-on acquisitions, disposals and joint ventures, including the creation of Haleon plc, the world-leading consumer healthcare company, through the combination of GSK’s consumer healthcare business firstly with Novartis’s business and subsequently in 2019 with Pfizer’s business. He is a member of GSK’s Corporate Executive Team and reports to the CEO. Prior to holding this position, he was responsible for the leadership of GSK’s business in Northern Europe from 2005 to 2008 and Central and Eastern Europe from 2002 to 2005. He joined Glaxo in 1994 in finance and progressed through a series of finance roles before becoming Finance Director of the European business in 1999. In addition to his current role, David is Chair of ViiV Healthcare Limited. ViiV is a joint venture between GSK, Pfizer and Shionogi, and focuses specifically on the research, development and global commercialisation of medicines to treat HIV/Aids. Raeesa Khan (35) Qualifications:Appointed:Classification: LLBJanuary 2024Group Company Secretary Further Information Raeesa Khan, in her capacity as Group Company Secretary, will take on governance oversight responsibility and the link between the Group Executive Committee and Aspen’s Board of Directors. Stephen Saad(61) Gus Attridge(64) Sean Capazorio(60) Lorraine Hill(62) Reginald Haman(52) Samer Kassem(51) Pauline Macdonald(49) Trevor Ziman(54) Chris Botha(47) Raeesa Khan(35) Stavros Nicolaou(60) Carnie van der Linde(56) Stephen Saad (61) Qualifications:Appointed:Classification: CA(SA), PhD (Commerce) Honoris CausaJanuary 1999Group Chief Executive Responsibilities Stephen is a founding shareholder of the Aspen Group, and his responsibilities include strategic positioning and global transactions, geographic expansion and product diversification of Aspen in developed and emerging markets as a leading multinational pharmaceutical company. Gus Attridge (64) Qualifications:Appointed:Classification: CA(SA)January 1999Group Chief Advisor Responsibilities Gus is a founding shareholder of Aspen and is responsible for providing insight and advice on strategic matters. Sean Capazorio (60) Qualifications:Appointed:Classification: CA(SA), Advanced Taxation Certificate (UNISA)January 1999Group Chief Financial Officer Responsibilities Sean is responsible for the strategic and financial well-being of the Group and for all the Group’s finance functions across Aspen’s businesses. Lorraine Hill (62) Qualifications:Appointed:Classification: BPharmApril 2021Group Chief Operations Officer Responsibilities Lorraine is responsible for multiple operational areas of the business, including strategic manufacturing, pharmaceutical affairs, new product development and strategic procurement. Reginald Haman (51) Qualifications:Appointed:Classification: MBA, PGDBA, ND, NHD, Graduate Diploma in Company DirectionApril 2021Group Chief Corporate Officer Responsibilities Reginald leads Aspen’s Group enablement, shared services, and governance functions, including technology, people, and strategic business processes. He joined the Social & Ethics Committee in September 2020 and was appointed as Executive director in March 2024. Samer Kassem (51) Qualifications:Appointed:Classification: CMA, CFM, CBM, MBAApril 2021Chief Executive Officer, Aspen Global Incorporated Further Information Samer leads and directs international operations; oversees, implements and executes all global Commercial Pharmaceuticals transactions. Pauline Macdonald (49) Qualifications:Appointed:Classification: BSc (Hons) Forensic & Analytical ChemistryApril 2024Group Executive: Supply Chain Responsibilities Pauline oversees international supply, quality and regulatory functions and drives Group Supply Chain standardisation, automation. Trevor Ziman (54) Qualifications:Appointed:Classification: CA(SA)April 2021Regional Chief Executive Officer, Asia Pacific Responsibilities Trevor implements strategy, performance delivery and trade across the Asia Pacific Commercial Pharmaceutical businesses and leads transactional activity in the region. Chris Botha (47) Qualifications:Appointed:Classification: CA(SA), ACMA, CGMA, Adv.Dip (Tax)April 2024Group Executive: Finance (Manufacturingand Commercial Pharma) Responsibilities Chris is responsible for the overall financial management and oversight of Aspen’s commercial and manufacturing businesses and the Group’s Holdings business unit. Raeesa Khan (35) Qualifications:Appointed:Classification: LLBJanuary 2024Group Company Secretary Further Information Raeesa Khan, in her capacity as Group Company Secretary, will take on governance oversight responsibility and the link between the Group Executive Committee and Aspen’s Board of Directors. Stavros Nicolaou (60) Qualifications:Appointed:Classification: B.Pharm, FPS (SA), PhD (Medicine) Honoris CausaApril 2021Group Senior Executive Strategic Trade Responsibilities Stavros initiates business development opportunities and is also key to the building and maintenance of strategic relations within industry and with all of Aspen’s stakeholders. Carnie van der Linde (56) Qualifications:Appointed:Classification: Bachelor of Dental Science (BDS)October 2022Senior Group Executive: Commercial (International Regions) Responsibilities Carnie develops and implements the Commercial Pharmaceuticals strategy and performance delivery across the Group’s international regions. Interim Results Fact Sheet 1 file(s) 0.00 KB Download Interim Results Presentation 1 file(s) 0.00 KB Download Illustrative Revenue Disclosure 1 file(s) 0.00 KB Download Interim Results Booklet 1 file(s) 0.00 KB Download Interim Results Booklet – Excel Download 1 file(s) 0.00 KB Download Interim Results Presentation Webcast 1 file(s) 0.00 KB Download Interim Results Short Form Announcement 1 file(s) 0.00 KB Download Additional Presentations and webcasts Stakeholder Update Call Presentation 15 January 2026 1 file(s) 0.00 KB Download Stakeholder Update Call Webcast 15 January 2026 1 file(s) 0.00 KB View Online   Annual Financial Statements 1 file(s) 1 MB Download Sustainability and ESG Data Supplement 1 file(s) 0.00 KB Download Social and Ethics Committee Report 1 file(s) 0.00 KB Download Notice of AGM 1 file(s) 32.00 KB Download Integrated Report 1 file(s) 0.00 KB Download Audit & Risk Committee Report 1 file(s) 0.00 KB Download Integrated Report – View Online Version 1 file(s) 0.00 KB View Online Access to Medicines Position Paper 1 file(s) 0.00 KB Download Carbon Disclosure Project – Climate Change and Water Security 1 file(s) 0.00 KB Download Equity Report – Pharmacare Workforce Profile 1 file(s) 0.00 KB Download IBIS Assurance Statement 1 file(s) 0.00 KB Download Sustainability and ESG Data Supplement 1 file(s) 0.00 KB Download Sustainability Materiality Assessment 1 file(s) 0.00 KB Download Aspen Key Facts 0 + SEDProjects 0 GlobalOffices 0 Manufacturing Facilities 0 + CountriesSupplied 0 + EmployeesGlobally Latest News Press Releases Our Stories Aspen delivers encouraging results, driven by strong Commercial Pharma, reshaped Manufacturing and value realisation from APAC divestment Read More Proposed divestment of Aspen Asia Pacific (excluding China) for R26.5 billion Read More Stephen Saad receives both AABLA Lifetime Achievement Award and African of the Year Award Read More Aspen highlights the rising diabetes disease burden Read More Aspen building momentum in Commercial Pharmaceuticals and Manufacturing strategy modified Read More Aspen celebrates 15 years of commitment to Nelson Mandela Day Read More Aspen delivers strong results and advances its strategic ambitions Read More Aspen announces local availability of Lilly’s Mounjaro Read More Aspen and SEMDSA highlight the alarming rise of non-communicable diseases on World Diabetes Day Read More Aspen to participate in the Investec CEO conference in London Read More Aspen North America Region’s Aspen Canada certified as a Great Place to Work® Read More Aspen continues to demonstrate its unwavering commitment to our various communities Read More Aspen partners with Reach for a Dream to bring joy to children with rare diseases  Read More Aspen launches its 2025 Integrated Report and retains Level 4 B-BBEE status Read More Aspen recognised for EY Excellence in Integrated Reporting Award Read More Our Purpose Find out more To improve the health and quality of life of patients. Our Vision Find out more To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally. Our Values Find out more Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group. Aspen Holdingswww.aspenpharma.comHotline (South Africa)0800 122 912Medical Careline (South Africa) 0800 118 088 Facebook-f Twitter-square Instagram Linkedin About Aspen Corporate Governance Prescription Over the Counter Injectables Manufacturing Regional Overviews We Care Ethics & Compliance Management Sustainability SED Initiatives Mandela Day Careers Careers at Aspen Aspen Jobs Contact Us ASPEN PHARMACARE HOLDINGS LTD: Switchboard: +27 31 580-8600 Aspen Place, 9 Rydall Vale Park Douglas Saunders Drive, La Lucia Ridge South Africa P.O. Box 25125, Gateway, Kwa‑Zulu Natal, 4321, South Africa © 2025 Aspen Holdings | Disclaimer | General Privacy Notice | Aspen PAIA & POPI Manual | Standard Terms of purchase of goods or services (STC) All Sites Asia Pacific Australia China New Zealand Philippines Europe Austria France France – NDB Netherlands Netherlands – Oss Russia Spain Switzerland Middle East & North Africa MENAT North America Canada USA South America Brazil Mexico Sub-Saharan Africa Ghana Kenya Mauritius Nigeria South Africa – SA Commercial South Africa – FCC South Africa HQ Tanzania Commercial Austria Canada EME France Germany Mexico – Aspen Labs Nigeria New Zealand Philippines Russia South Africa USA Manufacturing Aspen API Australia Brazil France – NDB Ghana Kenya Mexico South Africa – FCC Tanzania Closed Period Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026. The live presentation will take place in Cape Town at 08h30 on 2 March 2023. Corporate Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry. View our teams below: Human CapitalLegalSupply ChainTreasuryEthics & ComplianceRisk & SustainabilityDigital TechnologyTaxenusen-US1772678233https://aspenpharma.com

Сайтыңызды түзөтөсүзбү?

Сен эмне кылып жатасың?